首次公开发行网下配售限售股上市流通的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合"或"保荐机构"）作为 山东威高血液净化制品股份有限公司（以下简称"威高血净"、"公司"或"发行 人"）首次公开发行股票的保荐机构，根据《证券发行上市保荐业务管理办法》 《上海证券交易所股票上市规则》等有关规定，对公司首次公开发行网下配售限 售股上市流通事项进行了审慎核查，核查情况如下： 一、本次限售股上市类型 根据中国证券监督管理委员会《关于同意山东威高血液净化制品股份有限公 司首次公开发行股票注册的批复》（证监许可〔2025〕526 号），并经上海证券交 易所同意，公司首次向社会公开发行人民币普通股（A 股）41,139,407 股，并于 2025 年 5 月 19 日在上海证券交易所主板上市，发行完成后总股本为 411,394,066 股，其中有限售条件流通股 373,281,479 股，无限售条件流通股 38,112,587 股。 本次解除限售并上市流通的限售股为公司首次公开发行网下发行采用比例 限售方式形成的限售股，解除限售股份合计 1,254,745 股，占公司总股份比例为 0.3%。上述股份锁定期为自公司股 ...

Core Insights - The stock of Weigao Blood Products experienced a decline of 2.19% on November 11, with a trading volume of 263 million yuan. The net financing buy was negative at 527.39 million yuan, indicating a higher repayment than new purchases [1] Financing Overview - On November 11, Weigao Blood Products had a financing buy amount of 49.90 million yuan, with a total financing balance of 2.59 billion yuan, representing 15.85% of its market capitalization [1] - The company had no short selling activity on the same day, with both short selling and repayment amounts recorded as zero [1] Company Performance - As of September 30, the number of shareholders for Weigao Blood Products was 24,800, a decrease of 20.95% from the previous period. The average number of circulating shares per shareholder increased by 26.51% to 1,535 shares [2] - For the period from January to September 2025, the company reported a revenue of 2.736 billion yuan, reflecting a year-on-year growth of 3.45%. The net profit attributable to the parent company was 341 million yuan, marking a 7.92% increase year-on-year [2] Dividend Information - Since its A-share listing, Weigao Blood Products has distributed a total of 65.82 million yuan in dividends [3]

Core Viewpoint - Weigao Blood Products (603014) experienced a 2.73% increase in stock price with a trading volume of 5.34 billion yuan and a turnover rate of 30.19% on the day of reporting [1] Trading Activity - The stock was listed on the Shanghai Stock Exchange's "Dragon and Tiger List" due to its turnover rate reaching 30.19%, with a net selling amount of 30,250 yuan from brokerage seats [1] - The top five brokerage seats accounted for a total transaction volume of 1.01 billion yuan, with buying transactions amounting to 50.35 million yuan and selling transactions totaling 50.65 million yuan, resulting in a net sell of 30,250 yuan [1] - The largest buying brokerage was Southwest Securities, with a purchase amount of 19.10 million yuan, while the largest selling brokerage was East Asia Qianhai Securities, with a selling amount of 17.21 million yuan [1] Financial Performance - For the first three quarters, the company reported a total revenue of 2.736 billion yuan, reflecting a year-on-year growth of 3.45%, and a net profit of 341 million yuan, which is a year-on-year increase of 7.92% [2] - Over the past six months, the stock has appeared on the "Dragon and Tiger List" six times, with an average price drop of 2.84% the day after being listed and an average decline of 3.97% over the following five days [1] - The stock saw a net inflow of 15.59 million yuan from major funds today, with a significant single order net inflow of 18.45 million yuan, while large orders experienced a net outflow of 2.86 million yuan [1] - In the last five days, the net inflow of major funds amounted to 134 million yuan [1]

New Stock Listings - Daming Electronics (603376) listed at an issue price of 12.55 on November 6, 2025[1] - Haixia Innovation (300300) and Jiangbolong (301308) reported severe abnormal fluctuations on November 4, 2025[1] - Several companies including Xiangnan Xinchuan (300475) and Lansi Heavy Industry (603169) also reported abnormal fluctuations in late October[1] Abnormal Fluctuations - ST Bosen (002569) reported a fluctuation of 5939 on November 5, 2025[2] - Hailu Heavy Industry (002255) experienced a fluctuation of 5812 on November 5, 2025[2] - ST Aowei (002231) had a fluctuation of 5668 on November 5, 2025[2] - Rongke Technology (300290) reported a fluctuation of 4706 on November 3, 2025[2] - ST Xiongmao (600599) had a fluctuation of 5001 on November 4, 2025[2]

Core Viewpoint - The medical device sector experienced a slight decline of 0.31% on November 6, with Danaher Biomedical leading the losses, while the overall market indices showed gains, with the Shanghai Composite Index up by 0.97% and the Shenzhen Component Index up by 1.73% [1][2]. Group 1: Market Performance - The Shanghai Composite Index closed at 4007.76, increasing by 0.97% [1]. - The Shenzhen Component Index closed at 13452.42, increasing by 1.73% [1]. - The medical device sector saw a net outflow of 638 million yuan from major funds, while retail investors contributed a net inflow of 446 million yuan [2][3]. Group 2: Individual Stock Performance - Hualan Co., Ltd. (301093) saw a significant increase of 8.53%, closing at 44.00 yuan with a trading volume of 67,500 shares and a transaction value of 293 million yuan [1]. - Danaher Biomedical (920009) led the declines with a drop of 4.69%, closing at 83.50 yuan and a trading volume of 24,900 shares, resulting in a transaction value of 206 million yuan [2]. - Other notable gainers included Furuida (300049) with a 4.32% increase and a closing price of 74.56 yuan, and Kangzhong Medical (688607) with a 3.04% increase, closing at 29.81 yuan [1][2]. Group 3: Fund Flow Analysis - Major funds showed a net outflow in several stocks, including Furuida with a net outflow of 23.99 million yuan, while retail investors showed a net inflow of 25.27 million yuan [3]. - Dongfulong (300171) experienced a net inflow of 21.17 million yuan from major funds, indicating positive sentiment towards the stock [3]. - The overall trend indicates a mixed sentiment in the medical device sector, with some stocks attracting retail interest despite the overall outflow from major funds [2][3].

Core Insights - On November 5, Weigao Blood Purification experienced a decline of 3.98% in stock price, with a trading volume of 559 million yuan [1] - The company recorded a financing purchase amount of 107 million yuan and a net financing purchase of approximately 60.05 million yuan on the same day [1][2] - As of November 5, the total financing and securities lending balance for Weigao Blood Purification was 267 million yuan, representing 15.66% of its circulating market value [2] Financial Performance - For the period from January to September 2025, Weigao Blood Purification achieved a revenue of 2.736 billion yuan, reflecting a year-on-year growth of 3.45% [2] - The net profit attributable to the parent company for the same period was 341 million yuan, marking a year-on-year increase of 7.92% [2] Shareholder Information - As of September 30, the number of shareholders for Weigao Blood Purification was 24,800, a decrease of 20.95% compared to the previous period [2] - The average number of circulating shares per shareholder increased by 26.51% to 1,535 shares [2] Dividend Information - Since its A-share listing, Weigao Blood Purification has distributed a total of 65.8213 million yuan in dividends [3]

Core Viewpoint - Weigao Blood Products (603014) experienced a decline of 3.98% in stock price, with a trading volume turnover rate of 32.30% and a total transaction amount of 559 million yuan, indicating significant market activity and selling pressure [2][3]. Trading Activity - The stock was listed on the Shanghai Stock Exchange's "Dragon and Tiger List" due to its high turnover rate, with a net selling amount of 17.96 million yuan from brokerage seats [2]. - The top five brokerage seats accounted for a total transaction amount of 131 million yuan, with buying transactions amounting to 56.41 million yuan and selling transactions totaling 74.37 million yuan, resulting in a net selling of 17.96 million yuan [2]. - The largest buying brokerage was Zheshang Securities, with a purchase amount of 22.53 million yuan, while the largest selling brokerage was Huatai Securities, with a selling amount of 23.00 million yuan [2][3]. Recent Performance - Over the past six months, the stock has appeared on the "Dragon and Tiger List" five times, with an average price drop of 4.24% the day after being listed and an average decline of 6.30% over the following five days [3]. - On the day of the report, the stock saw a net outflow of 66.82 million yuan in main funds, with large orders contributing to a net outflow of 41.33 million yuan and 25.49 million yuan respectively. However, there was a net inflow of 119 million yuan in the past five days [3]. Financial Performance - The company reported its third-quarter results on October 31, showing a total revenue of 2.736 billion yuan for the first three quarters, representing a year-on-year growth of 3.45%. The net profit reached 341 million yuan, reflecting a year-on-year increase of 7.92% [3].

Market Overview - The Shanghai Composite Index fell by 0.41% to close at 3960.19 points, with a high of 3985.88 points during the day [1] - The Shenzhen Component Index decreased by 1.71% to close at 13175.22 points, reaching a maximum of 13399.92 points [1] - The ChiNext Index dropped by 1.96% to end at 3134.09 points, with a peak of 3207.1 points [1] Margin Trading and Securities Lending - The total margin trading and securities lending balance in the Shanghai and Shenzhen markets was 24836.48 billion yuan, with a financing balance of 24657.13 billion yuan and a securities lending balance of 179.35 billion yuan [2] - The margin trading and securities lending balance decreased by 31.31 billion yuan compared to the previous trading day [2] - The Shanghai market's margin trading balance was 12668.67 billion yuan, down by 4.84 billion yuan, while the Shenzhen market's balance was 12167.81 billion yuan, down by 26.47 billion yuan [2] Top Margin Buying Stocks - The top three stocks by margin buying amount were: - Sunshine Power with 29.61 billion yuan - Zhongji Xuchuang with 26.72 billion yuan - Xinyisheng with 19.06 billion yuan [3] Fund Issuance - One new fund was issued yesterday: - Industrial Securities CSI Technology Advantage Growth 50 Strategy ETF [4][5] Top Net Buying on Dragon and Tiger List - The top 10 net buying amounts on the Dragon and Tiger list were led by: - Wanlima with 262.27 million yuan - Fulongma with 238.73 million yuan - Haixia Innovation with 209.03 million yuan [6][7]

Market Overview - On November 4, the Shanghai Composite Index fell by 0.41%, with the total margin trading balance at 24,916.23 billion yuan, a decrease of 31.40 billion yuan from the previous trading day [1] - The margin trading balance in the Shanghai market was 12,668.67 billion yuan, down by 4.84 billion yuan; in the Shenzhen market, it was 12,167.81 billion yuan, down by 26.47 billion yuan; and in the Beijing Stock Exchange, it was 79.75 billion yuan, down by 862.47 thousand yuan [1] Industry Performance - Among the industries tracked by Shenwan, 18 sectors saw an increase in margin balances, with the computer industry leading with an increase of 3.92 billion yuan, followed by basic chemicals and food & beverage sectors with increases of 3.40 billion yuan and 3.07 billion yuan, respectively [1] Individual Stock Performance - A total of 1,793 stocks experienced an increase in margin balances, accounting for 47.94% of the total, with 262 stocks seeing an increase of over 5% [1] - The stock with the largest increase in margin balance was Danna Biological, with a latest margin balance of 15.96 million yuan, reflecting a 386.84% increase, although its stock price fell by 16.75% on the same day [1] - Other notable stocks with significant margin balance increases included Weigao Blood Products (603014) and Everbright Jiabao (600622), with increases of 112.18% and 61.73%, respectively [1] Top Margin Balance Increases - The top 20 stocks by margin balance increase averaged a rise of 1.22%, with the highest performers being Jingquanhua (002885), Weigao Blood Products, and Hailu Heavy Industry (002255), which rose by 10.02%, 10.00%, and 9.98%, respectively [2] - Conversely, Danna Biological, Baicheng Pharmaceutical (301096), and Boying Special Welding (301468) saw declines of 16.75%, 10.78%, and 6.52%, respectively [2] Notable Margin Balance Decreases - Among the stocks with significant margin balance decreases, Ruixing Co. (920717) had the largest drop, with a margin balance of 1.11 million yuan, down by 60.33% [4] - Other stocks with notable decreases included Wangcheng Technology and Luqiao Information, with declines of 38.43% and 26.47%, respectively [4]

Group 1: New Stock Offering - A new stock, Dapeng Industrial, has an offering code of 920091 with an issue price of 9.00 yuan per share and a subscription limit of 675,000 shares [2] Group 2: Holiday Arrangement - The State Council has announced the holiday schedule for 2026, including specific dates for New Year's Day, Spring Festival, Qingming Festival, Labor Day, Dragon Boat Festival, Mid-Autumn Festival, and National Day [2] Group 3: Central Bank Operations - The People's Bank of China will conduct a 700 billion yuan reverse repurchase operation to maintain liquidity in the banking system, with a term of 3 months [3] Group 4: Semiconductor Industry - The Ministry of Commerce expressed hope for constructive solutions regarding ASML Semiconductor, urging the Netherlands to maintain stable trade relations with China [3] Group 5: AI in Healthcare - The National Health Commission has released guidelines to promote AI applications in healthcare, aiming for widespread use of intelligent decision-making and patient services by 2030 [4] Group 6: Alcohol Industry in Guizhou - The Guizhou Provincial Department of Commerce is seeking opinions on transforming the alcohol sales model to better meet consumer demands and expand overseas markets [5] Group 7: Manufacturing Sector Insights - Guangfa Securities noted a recovery in manufacturing demand and investment, suggesting a focus on emerging industries and the AI supply chain [8] Group 8: Oil Market Analysis - Everbright Securities reported that OPEC+ has paused production increases, which may support oil prices in the short term, while maintaining a long-term positive outlook on major oil companies [9]